随着广谱抗菌药物及免疫抑制剂的使用,人口老龄化社会现象,抗菌药物耐药问题日益严重。和抗菌药物耐药相比,研制一种新型的抗菌药物的速度远远落后于前者。耐药的革兰阳性(G~+)球菌是导致临床抗感染治疗失败的主要原因之一。达巴万星(dalbavancin)为Vicuron Pharmaceuticals公司开发的一种新型半合成糖肽类抗生素,为替考拉宁 With the use of broad-spectrum antimicrobial agents and immunosuppressants, the social phenomenon of an aging population and the problem of antimicrobial resistance are becoming increasingly serious. Compared with antimicrobial resistance, the development of a new type of antimicrobial drug lags far behind the former. Drug-resistant Gram-positive (G ~ +) cocci is one of the main reasons for the failure of clinical anti-infective therapy. Dalbavancin is a new type of semi-synthetic glycopeptide antibiotic developed by Vicuron Pharmaceuticals Company. It is teicoplanin